Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 08, 2018

SELL
$8.03 - $11.25 $134,936 - $189,045
-16,804 Closed
0 $0
Q3 2017

Nov 08, 2017

BUY
$8.35 - $10.5 $140,313 - $176,442
16,804
16,804 $176,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $706M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Condor Capital Management Portfolio

Follow Condor Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Condor Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Condor Capital Management with notifications on news.